Thymidine Phosphorylase Antibody P-GF.44C

	Catalog No	Formulation	Size	Price (USD)
	V3416-100UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	100 ug	519
Formulation
	V3416-20UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	20 ug	229
Formulation
	V3416SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug	519
Formulation

Bulk quote request

›

Western blot testing of human spleen lysate with Thymidine Phosphorylase antibody (clone P-GF.44C). Predicted molecular weight ~55 kDa.

SDS-PAGE Analysis of Purified, BSA-Free Thymidine Phosphorylase Antibody (clone P-GF.44C). Confirmation of Integrity and Purity of the Antibody.

IHC testing of FFPE human placenta with Thymidine Phosphorylase antibody (clone P-GF.44C). Required HIER: requires boil tissue sections in 10mM citrate buffer, pH 6, for 10-20 min followed by cooling at RT for 20 min.

Species Reactivity	Human, Mouse, Rat
Format	Purified
Clonality	Monoclonal (mouse origin)
Isotype	Mouse IgG1, kappa
Clone Name	P-GF.44C
Purity	Protein G affinity chromatography
Buffer	1X PBS, pH 7.4
UniProt	P19971
Localization	Cytoplasmic, nuclear
Applications	Western blot : 0.5-1ug/ml Immunoprecipitation : 0.5-1ug/500ug protein lysate Immunohistochemistry (FFPE) : 1-2ug/ml for 30 min at RT
Limitations	This Thymidine Phosphorylase antibody is available for research use only.
	Review this product on BioCompare and get a $20 Amazon gift card

Description

Recognizes a 485 amino acid protein (55 kDa monomer / 110 kDa homodimer), identified as platelet-derived endothelial growth factor (PD-ECGF), also called Thymidine Phosphorylase (TP, Tymp) or Gliostatin. In the presence of inorganic orthophosphate, it catalyzes the reversible phospholytic cleavage of thymidine and deoxyuridine to their corresponding bases and 2-deoxyribose-1-phosphate. It is both chemotactic and mitogenic for endothelial cells and a non-heparin binding angiogenic factor present in platelets. Its enzymatic activity is crucial for angiogenic activity (metabolite is angiogenic). Higher levels of serum TP/PD-ECGF are observed in cancer patients. It is also involved in transformation of fluoropyrimidines, cytotoxic agents used in the treatment of a variety of malignancies, into active cytotoxic metabolites (e.g. 5 -deoxy-5-fluorouridine to 5-FU). High intra-cellular levels of TP/PD-ECGF are associated with increased chemosensitivity to such antimetabolites.

Application Notes

The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the Thymidine Phosphorylase antibody to be titered up or down for optimal performance.